Brooklyn ImmunoTherapeutics Completes Acquisition of Novellus Therapeutics

Brooklyn ImmunoTherapeutics, Inc. has announced that it had completed its acquisition of Novellus Therapeutics Limited. Novellus is developing next‑generation engineered MSC therapies using extensively patented mRNA-based cell reprogramming and gene editing technologies.